Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TTPH Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Tetraphase Pharmaceuticals Stock (NASDAQ:TTPH) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get TTPH alerts:Sign Up Key Stats Today's Range$2.18▼$2.2750-Day Range$2.20▼$2.2052-Week Range$0.56▼$8.60Volume282,689 shsAverage Volume932,542 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Receive TTPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tetraphase Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TTPH Stock News HeadlinesInfinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News SummaryFebruary 26, 2023 | benzinga.comTetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test ResultsAugust 30, 2022 | thestreet.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 4, 2024 | Crypto 101 Media (Ad)Tetraphase Executive Profits Hours Before Stock PlummetsAugust 20, 2022 | thestreet.comTTPH_old Historical DataApril 4, 2022 | investing.com10 Worst NASDAQ Biotech Stocks in the Third QuarterJanuary 16, 2022 | thestreet.comSee More Headlines TTPH Stock Analysis - Frequently Asked Questions How were Tetraphase Pharmaceuticals' earnings last quarter? Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.32. The biopharmaceutical company earned $1.76 million during the quarter, compared to analyst estimates of $2.45 million. Tetraphase Pharmaceuticals had a negative trailing twelve-month return on equity of 210.86% and a negative net margin of 798.18%. When did Tetraphase Pharmaceuticals' stock split? Tetraphase Pharmaceuticals shares reverse split on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Tetraphase Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tetraphase Pharmaceuticals investors own include Alcoa (AA), Aurinia Pharmaceuticals (AUPH), General Electric (GE), Bank of America (BAC), OPKO Health (OPK), Novavax (NVAX) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings5/07/2020Today11/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TTPH CUSIPN/A CIK1373707 Webwww.tphase.com Phone617-715-3600FaxN/AEmployees119Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($22.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,080,000.00 Net Margins-798.18% Pretax MarginN/A Return on Equity-210.86% Return on Assets-121.73% Debt Debt-to-Equity Ratio0.06 Current Ratio3.66 Quick Ratio3.56 Sales & Book Value Annual Sales$7.38 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.68 per share Price / Book0.33Miscellaneous Outstanding Shares7,263,000Free FloatN/AMarket Cap$15.98 million OptionableOptionable Beta2.33 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:TTPH) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tetraphase Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tetraphase Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.